Inspection Record

Custom Meds Inc. — FDA 483 Findings

US FDAInspected 2016-04-19Published 2024-01-17 3 findingsLaboratory and QC controls

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength ofe11ch active ingredient prior to release.

2Laboratory and QC controls

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing .

3Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Custom Meds Inc. company profile — full history US FDA documents, 2024 Go to Findings search